Alvarez & Marsal Expands Its Capital Markets & Accounting Advisory Senior Talent Globally
Leading global professional services firm Alvarez & Marsal (A&M) announced the appointment of Stockholm-based Annika Melin Jakobsson and New York-based Patricia Alonso de la Fuente as Global Transaction Advisory Group (TAG) Managing Directors within its Capital Markets & Accounting Advisory (CMAA) practice. Ms. Melin Jakobsson will develop A&M’s CMAA offering in the Nordics and EMEA. Ms. Alonso de la Fuente will support CMAA in the US, Spain and its continued Latin American (LatAm) expansion.
Paul Aversano, Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “Building our CMAA offering in the Nordics and EMEA while expanding it across LatAm and Spanish speaking countries enhances our independent capital markets and advisory accounting advice capabilities for private equity (PE) and multinational corporate clients seeking transaction support. Following on CMAA Managing Director Ayres Moura’s recent hire, Annika’s and Patricia’s joining aligns with our strategic talent, capabilities, and geographic growth plan.”
Ms. Melin Jakobsson, A&M’s Nordic CMAA practice Leader who will support this offering across EMEA, specializes in initial public offerings (IPO), carve-outs, capital markets transactions, corporate governance, risk, compliance, and all mergers and acquisitions (M&A) lifecycle aspects. She advises board and management teams, in listed and non-listed companies, and has led national and international large- mid- and small cap IPOs and capital markets transactions. Ms. Melin Jakobsson ensures clients’ IPO readiness, and once listed, their alignment with capital markets’ governance, risk and compliance and financial reporting requirements.
Ms. Alonso de la Fuente’s global mindset and local expertise crisscrosses her extensive cross-border and cross-functional market transaction experience. She focuses on IPOs, acquisitions, divestitures, international financial reporting standards (IFRS), US generally accepted accounting principles (GAAP) conversions and complex technical accounting matters. Additionally, she has led complex, cross-functional M&A and IPO projects and developed holistic solutions for clients across diverse sectors in the Americas and Europe.
Phil Mitchell, EMEA TAG Practice Co-Leader, noted, “A&M’s freedom from audit conflicts and integrated platform enables independent capital markets and accounting advice that maximizes value for PE and corporate clients. Annika’s and Patricia’s combined expertise solidifies our global CMAA offering and elevates our exit readiness capabilities.”
Previously, Ms. Melin Jakobsson served as Managing Partner for EY’s Nordic Capital Markets group and Managing Partner for KPMG’s Deal Advisory Capital Markets Group in Sweden. While at KPMG, she also served as a member of its board of directors.
Prior to joining A&M, Ms. Alonso de la Fuente served with KPMG, most recently as Partner in Deal Advisory in New York, along with leading that firm’s Capital Markets and Accounting Advisory Services US-LatAm corridor.
Mses. Melin Jakobsson and Alonso de la Fuente, said, “Capital markets are part of the transaction lifecycle. With tailored teams to meet needs and demands, A&M’s business model supports clients wherever we are in that cycle. Across the transaction spectrum, from aligning IPO readiness to planning exits, now is the time for corporates and PE to prepare.”
Ms. Melin Jakobsson earned a master’s degree in law from Uppsala University and has been part of the Swedish Nasdaq Listing Auditor’s team for 10+ years. She has been engaged as a capital market specialist by the Swedish Institute for the Accountancy Profession, Accountancy Europe and the Centre for Business and Policy Studies.
Ms. Alonso de la Fuente holds a bachelor’s degree in business administration from Complutense University, Madrid, and Leeds, United Kingdom.
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 9,000 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what is really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
About Alvarez & Marsal Global Transaction Advisory Group
A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.
The firm’s Global Transaction Advisory Group includes over 950 professionals in 37 offices worldwide. Our global team has extensive industry knowledge across multiple sectors and is free from audit-based conflicts of interests.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122439270/en/
Contact information
Sandra Sokoloff, Senior Director of Global Public Relations
Alvarez & Marsal, +1 212-763-9853
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom